Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…er tumor necrosis induced by TATE could enhance the efficacy of pembrolizumab (pembro).Methods Subjects with mCRC-MSS who had progressed on 2…
…ety signals after 9 months of follow-up.All 7 patients received A2B694, were efficacy-evaluable, and had A2B694 detected post-infusion…
…d.aaf2341Leong JW, Chase JM, Romee R, et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity I…
…al immunotherapy approaches to date.Conclusions Taken together, TTX-080 offers a differentiated mechanism-of-action that has the potent…
…inhibition dependent changes in anti-tumor immunity.Conclusions BAY2965501 demonstrates pharmacodynamic PoM in monotherapy and combination…
…2 and Flu 30 mg/m2 x 4 days, followed by a one-time infusion of IMA203 (1-10x 109 TCR T cells), and low-dose IL-2 (1 M IU QD x5 days, …
…in response to both single-agent and combination treatment with carboplatin and docetaxel. Multiparameter flow cytometry demonstrated a het…
…ttps://doi.org/10.1016/j.annonc.2022.01.051Kang M, Yoo S, Ma S. BAL0891 as a dual kinase inhibitor inducing anti-tumor immunity: A prom…
… in vivo with the orally bioavailable, small molecule inhibitor PLN-101095, which was administered in the mouse chow.Results and Conclusio…
…mbrolizumab (n = 5). Tyrosine kinase inhibitors (TKIs) included lenvatinib (n = 16) and sorafenib (n = 13).Results With a median follow-up…
…mab and chemotherapy. These findings highlight the potential of STK-012 to overcome key limitations of the next wave immunotherapies by…
… cancer (NSCLC) where immunotherapy is standard of care.Methods Daraxonrasib, a RAS(ON) multi-selective inhibitor, and elironrasib, a RAS(ON…